UCART19, AN ALLOGENEIC ANTI-CD19 CAR T-CELL PRODUCT, IN HIGH RISK ADULT PATIENTS WITH CD19+ RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: PRELIMINARY RESULTS OF PHASE I CALM STUDY

EHA Library, Reuben Benjamin, 214674

LONG-TERM SURVIVAL OF ADULTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BCP-ALL) AFTER TREATMENT WITH BLINATUMOMAB AND SUBSEQUENT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

EHA Library, Nicola Goekbuget, 214675

RE-THINKING THE PROGNOSTIC RELEVANCE OF A CD20 EXPRESSION CUT-OFF OF 20% IN ACUTE LYMPHOBLASTIC LEUKAEMIA: INITIAL RESULTS FROM THE UKALL14 TRIAL

EHA Library, Katharine Bailey, 214676

IMPROVEMENT OF PATIENT-REPORTED QUALITY OF LIFE FOLLOWING TISAGENLECLEUCEL INFUSION IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Library, Andre Baruchel, 214677

OUTCOMES WITH INOTUZUMAB OZOGAMICIN IN PATIENTS WITH PHILADELPHIA CHROMOSOME–POSITIVE RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Library, Giovanni Martinelli, 214678

IMPACT OF MINIMAL RESIDUAL DISEASE STATUS IN CLINICAL OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH INOTUZUMAB OZOGAMICIN IN THE PHASE 3 INO-VATE TRIAL

EHA Library, Nicola Gökbuget, 214679

EXTENSIVE SAFETY PROFILE OF INOTUZUMAB OZOGAMICIN IN RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS ENROLLED IN THE PHASE 3 INO-VATE TRIAL

EHA Library, Daniel DeAngelo, 214680

BLINATUMOMAB AND TYROSINE KINASE INHIBITORS COMBINATION IN RELAPSED/REFRACTORY ACUTE LYMPHOBALTIC LEUKEMIA: PRIMARY RESULTS AND LATE EVENTS

EHA Library, Andrey Sokolov, 214681

CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PEDIATRIC/ADOLESCENT/YOUNG ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN FIRST RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANT IN CR1

EHA Library, Peter Bader, 214682

INDIRECT TREATMENT COMPARISON OF BLINATUMOMAB VS INOTUZUMAB OZOGAMICIN FOR TREATING ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA RECEIVING ZERO OR ONE PRIOR SALVAGE THERAPY

EHA Library, Ze Cong, 214683

LONG TERM OUTCOME OF 138 ALO TRANSPLANTS IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA ON A SINGLE TRANSPLANT CENTER IN SPAIN

EHA Library, Irati Ormazabal Velez, 214684

ROBUST IN VIVO SYNERGY BETWEEN THE ANTI-CD33 ADC, IMGN779 AND THE FLT3 INHIBITOR QUIZARTINIB IN HUMAN FLT3-ITD AML MODELS.

EHA Library, Krystal Watkins, 214685

NOVEL MUTATIONS AND TRANSLOCATIONS INVOLVING NUCLEOPHOSMIN (NPM1) GENE IN ACUTE MYELOID LEUKEMIA (AML) AND LEADING TO ABERRANT CYTOPLASMIC NPM1

EHA Library, Maria Paola Martelli, 214686

THE LSC17 SCORE ALLOWS RISK STRATIFICATION IN PEDIATRIC ACUTE MYELOID LEUKEMIA

EHA Library, Nicolas Duployez, 214687

MUTATION PROFILE AND BENEFIT OF GEMTUZUMAB OZOGAMICIN IN ACUTE MYELOID LEUKEMIA PATIENTS TREATED IN THE ALFA-0701 TRIAL

EHA Library, Elise Fournier, 214688

MOLECULAR PATHOGENESIS OF DISEASE PROGRESSION IN MLL-REARRANGED AML

EHA Library, Hideki Makishima, 214689

GENOMIC CHARACTERISTICS OF ACUTE ERYTHROID LEUKEMIA

EHA Library, June Takeda, 214690

FUNCTIONAL PROTEOMICS ANALYSIS OF AML-RELATED NUP98-FUSION PROTEIN INTERACTOMES

EHA Library, Stefan Terlecki-Zaniewicz, 214691

THE PNT DOMAIN OF ERG REGULATES HEMATOPOIETIC STEMNESS, YET IS NOT ESSENTIAL FOR ERG INDUCED ACUTE MYELOID LEUKEMIA

EHA Library, Eitan Kugler, 214692

FUNCTIONAL ANALYSIS OF EPIGENETIC AND TRANSCRIPTOMIC EFFECTS OF CEBPA MUTATIONS IN ACUTE MYELOID LEUKEMIA

EHA Library, Elizabeth Heyes, 214693

DETECTION OF MEASURABLE RESIDUAL DISEASE (MRD) BY ULTRADEEP NEXT GENERATION SEQUENCING (NGS) IS HIGHLY PREDICTIVE OF OUTCOME IN NPM1 MUTATED ACUTE MYELOID LEUKEMIA (AML)

EHA Library, Nikhil Patkar, 214694

PREFERENTIAL IN VITRO AND IN VIVO INDUCTION OF ENDOGENOUS RETROVIRUS TRANSCRIPTION FROM A MONOALLELIC CHROMOSOME 7Q IN DECITABINE (DAC) TREATED AML BLASTS

EHA Library, Gabriele Greve, 214695

NOVEL DEEP TARGETED SEQUENCING METHOD FOR MINIMAL RESIDUAL DISEASE MONITORING IN ACUTE MYELOID
 LEUKEMIA

EHA Library, Maria Esther Onecha Fuente, 214696

A SYSTEMATIC EVALUATION OF PROGNOSTIC GENE EXPRESSION SIGNATURES IN 1208 ACUTE MYELOID LEUKEMIA PATIENTS REVEALS NOVEL INSIGHTS FOR FUTURE RESEARCH AND CLINICAL APPLICATION

EHA Library, Dominik Beck, 214697

AN ARTIFICIAL NEURAL NETWORK-BASED APPROACH IDENTIFIES A POWERFUL 3-GENE PREDICTOR OF ADVERSE PROGNOSIS IN ACUTE MYELOID LEUKAEMIA

EHA Library, Sarah Wagner, 214698

PROFILING AND FUNCTIONAL ANALYSIS OF CIRCULAR RNAS IN ACUTE PROMYELOCYTIC LEUKEMIA AND THEIR DYNAMIC REGULATION DURING ALL-TRANS RETINOIC ACID TREATMENT

EHA Library, Shufen Li, 214699

PML-RARA INTERACTS WITH NRF2, INHIBITS ITS ACTIVITY AND INCREASES THE SENSITIVITY OF ACUTE PROMYELOCITIC LEUKEMIA CELLS TO ASCORBATE

EHA Library, Nelida I. Noguera, 214700

A POSSIBLE FIRST TIER SCREENING TEST TO DETECT TRANSLOCATIONS IN LEUKEMIAS USING TARGETED LOCUS AMPLIFICATION

EHA Library, Eva Van Den Berg-De Ruiter, 214701

FUNCTIONAL EVALUATION AND MECHANISM RESEARCH OF KEL AND CIRC-KEL IN AEL

EHA Library, Hui Jin, 214702

MOLECULAR PROFILES IN AML PATIENTS OLDER THAN 70 YEARS OF AGE

EHA Library, Montserrat Hoyos Colell, 214704

COMPARISON OF WHOLE GENOME ANALYSIS APPROACHES FOR DETECTION OF MAJOR CHROMOSOMAL ABERRATIONS USING A DIVERSE SET OF LEUKEMIA PATIENTS

EHA Library, Sven Twardziok, 214705

SOMATIC MUTATIONS IN RELAPSED ACUTE MYELOID LEUKEMIA

EHA Library, Samuli Eldfors, 214706

EXPRESSION OF PIWI-INTERACTING RNAS (PIRNAS) AND ITS PROGNOSTIC IMPLICATION IN ACUTE MYELOID LEUKEMIA (AML): A 3-PIRNA SCORING SYSTEM PREDICTS PROGNOSIS IN AML PATIENTS

EHA Library, Ta-Chuan Yu, 214707

BASOPHIL-LINEAGE COMMITMENT IN ACUTE PROMYELOCYTIC LEUKEMIA PREDICTS FOR SEVERE BLEEDING AFTER STARTING THERAPY

EHA Library, Alberto Orfao, 214708

RECURRENCE OF THE 8Q24 REARRANGEMENT IN BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM AND ITS ASSOCIATION WITH IMMUNOBLASTOID CYTOMORPHOLOGY, MYC EXPRESSION, AND DRUG RESPONSE

EHA Library, Kana Sakamoto, 214709

COMBINATION OF FLT3 INHIBITOR QUIZARTINIB AND MDM2 INHIBITOR MILADEMETAN RESULTS IN GREATER PRE-CLINICAL ANTI-LEUKEMIC ACTIVITY IN FLT3-ITD MUTANT/P53 WILD-TYPE ACUTE MYELOID LEUKEMIA MODELS

EHA Library, Michael Andreeff, 214710

A GROUP OF EMA-APPROVED IMMUNOMODULATORS TARGETS AML STEM CELLS BY SABOTAGING THE CELLULAR RECYCLING MACHINERY

EHA Library, Josep Maria CORNET MASANA, 214711

EXPLORING ALTERNATIVE TREATMENTS TO IMPROVE OUTCOME FOR PEDIATRIC PATIENTS WITH ACUTE MYELOID LEUKEMIA

EHA Library, Katrina Lappin, 214712

ADDITION OF CRENOLANIB TO STANDARD INDUCTION AND CONSOLIDATION THERAPIES IMPROVED LONG-TERM OUTCOMES IN NEWLY DIAGNOSED FLT3-MUTANT AML PATIENTS ≤ 60 YEARS OLD

EHA Library, Roland B. Walter, 214713

COMBINATION OF IDARUBICIN, CYTARABINE AND CLADRIBINE AS INDUCTION REGIMEN FOR UNTREATED ADULT AML AGED 60 OR YOUNGER: A PHASE III RANDOMIZED CLINICAL TRIAL

EHA Library, Jia Chen, 214714

REASSESSING THE PROGNOSTIC SIGNIFICANCE OF RECURRING CHROMOSOMAL ABNORMALITIES AND FLT3-ITD IN ACUTE MYELOID LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION: AN ALWP/EBMT ANALYSIS

EHA Library, Jonathan Canaani, 214715

DECITABINE IN DAY TO DAY PRACTICE IN UNTREATED AML, RISK FACTORS AND COMPARISON WITH DACO16

EHA Library, Adolfo De La Fuente, 214717

INITIAL PHASE 1 RESULTS OF THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY HU5F9-G4 IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA PATIENTS

EHA Library, Paresh Vyas, 214718

IMPACT OF CONCOMITANT EXPRESSION OF CD200 AND BCL2 ON OUTCOME OF ACUTE MYELOID LEUKEMIA

EHA Library, Mario Tiribelli, 214719

TP53 MUTATIONS NEGATIVELY IMPACT SURVIVAL OF ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH STANDARD DOSES OF HYPOMETHYLATING AGENTS

EHA Library, Pierre Bories, 214720

CHARACTERISTICS AND OUTCOME OF PATIENTS WITH ACUTE MYELOID LEUKEMIA AND T(8;16)(P11;P13): RESULTS FROM AN INTERNATIONAL COLLABORATION

EHA Library, Sabine Kayser, 214721

A PHASE 1 DOSE ESCALATION STUDY OF THE IDH1M INHIBITOR, FT-2102, IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS)

EHA Library, Maria Baer, 214722

RISK FACTORS IN RELAPSE/REFRACTORY AML TREATED WITH DECITABINE

EHA Library, Adolfo De La Fuente, 214723

SAFETY AND PHARMACOKINETICS OF A NOVEL ORAL CAPSULE FORMULATION OF ARSENIC TRIOXIDE, ORH-2014, IN PATIENTS WITH ADVANCED HEMATOLOGIC DISORDERS

EHA Library, Farhad Ravandi-Kashani, 214724

OUTCOMES BY NUMBER OF INDUCTION CYCLES WITH CPX-351 VERSUS 7+3 CHEMOTHERAPY IN OLDER ADULTS WITH NEWLY DIAGNOSED, HIGH-RISK/SECONDARY ACUTE MYELOID LEUKEMIA (SAML)

EHA Library, Jorge Cortes, 214725

POST HOC EXPLORATORY ANALYSIS OF TWO PHASE 2 TRIALS OF QUIZARTINIB MONOTHERAPY IN PATIENTS WITH FLT3-ITD MUTATED RELAPSED/REFRACTORY AML AND PRIOR FLT3 TYROSINE KINASE INHIBITOR TREATMENT

EHA Library, Jorge Cortes, 214726

RISK FACTORS OF EARLY DEATH FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE PROMYELOCYTIC LEUKEMIA UNDER THE TREATMENT OF ATRA, ATO WITH OR WITHOUT CHEMOTHERAPY

EHA Library, Li Chen, 214728

PHASE II STUDY INCORPORATING A NOVEL BH3-PROFILING BIOMARKER APPROACH OF ALVOCIDIB FOLLOWED BY CYTARABINE AND MITOXANTRONE IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML)

EHA Library, Joshua F. Zeidner, 214729

OUTCOME OF A REAL-LIFE POPULATION OF ACUTE PROMYELOCYTIC LEUKEMIA TREATED ACCORDING TO PETHEMA LPA 2005 PROTOCOL: THE POLISH ADULT LEUKEMIA GROUP (PALG) EXPERIENCE.

EHA Library, Marta Sobas, 214730

GLASDEGIB IMPROVED OVERALL SURVIVAL IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS) WHO ACHIEVED COMPLETE REMISSION (CR) AND THOSE WHO DID NOT ACHIEVE CR

EHA Library, Jorge Cortes, 214731

HIGH COMPLETE REMISSION RATES WITH ORAL SYK INHIBITOR ENTOSPLETINIB (GS-9973) IN ACUTE MYELOID LEUKEMIA PATIENTS ASSOCIATED WITH HIGH HOXA9/MEIS1 EXPRESSION.

EHA Library, Veerendra Munugalavadla, 214732

WEEKEND VERSUS WEEKDAY DIAGNOSIS AND EARLY MORTALITY IN ACUTE PROMYELOCYTIC LEUKEMIA: A POPULATION-BASED ANALYSIS IN THE NETHERLANDS

EHA Library, Avinash Dinmohamed, 214733

DECITABINE IN PATIENTS WITH NEWLY DIAGNOSED AND RELAPSED ACUTE MYELOID LEUKEMIA (AML): THE REAL LIFE EXPERIENCE FROM THE “ITALIAN TRIVENETO REGISTRY”.

EHA Library, Carla Fili, 214734

PROGNOSTIC IMPACT OF SKELETAL MUSCLE ASSESSED BY COMPUTED TOMOGRAPHY SCAN IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

EHA Library, Nobuhiko Nakamura, 214735

INCIDENCE OF MARROW NEOPLASMS IN BREAST CANCER SURVIVORS: A NATIONAL POPULATION-BASED COHORT STUDY

EHA Library, Norbert Vey, 214736

WILMS TUMOR 1 EXPRESSION IN ACUTE MYELOID LEUKEMIA CORRELATES WITH CYTOGENETICS OR COLLABORATIVE MUTATIONS: HOKKAIDO LEUKEMIA NET STUDY

EHA Library, Daisuke Hidaka, 214737

OUTCOMES FOR T(9;11) PATIENTS ARE NO BETTER THAN FOR OTHER REARRANGEMENT PARTNERS IN 11Q23-REARRANGED ADULT AML: A COMPREHENSIVE REVIEW OF MLL-R AML TREATED AT MEMORIAL SLOAN KETTERING CANCER CENTER

EHA Library, Kamal Menghrajani, 214738

HYPOMETILATING AGENTS (HMA) AS SALVAGE THERAPY IN RELAPSED OR REFRACTORY AML: AN ITALIAN 9-CENTER RETROSPECTIVE STUDY

EHA Library, Marica Laurino, 214739

COMPREHENSIVE ANALYSIS OF THE CORE-BINDING FACTOR ACUTE MYELOID LEUKEMIA WITH KOREAN AML REGISTRY

EHA Library, Ho-Jin Shin, 214740

REAL WORLD EVIDENCE ON THE BURDEN OF ILLNESS EXPERIENCED BY PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AND SYSTEMIC MYCOSES

EHA Library, Anna Forsythe, 214741

EVALUATION OF FOOD EFFECT ON PHARMACOKINETICS OF IVOSIDENIB (AG-120), AN ORAL, POTENT, TARGETED, SMALL MOLECULE INHIBITOR OF MUTANT IDH1, IN HEALTHY SUBJECTS

EHA Library, Bin Fan, 214742

AZACITIDINE FRONTLINE AND SALVAGE THERAPY FOR ACUTE MYELOID LEUKEMIA PATIENTS. CLINICAL EXPERIENCE AND DEVELOPMENT OF RISK SCORE

EHA Library, Silvia Imbergamo, 214743

MYELOID SARCOMAS IN AML TRANSLOCATION (8;21) IS IT STILL A FAVOURABLE RISK GROUP?

EHA Library, Rohan Halder, 214744

AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH REFRACTORY LARGE B CELL LYMPHOMA: DURABILITY OF RESPONSE IN ZUMA-1

EHA Library, Olalekan O. Oluwole, 214745

THE NOVEL SYK/JAK INHIBITOR CERDULATINIB DEMONSTRATES GOOD TOLERABILITY AND CLINICAL RESPONSE IN A PHASE 2A STUDY IN RELAPSED/REFRACTORY PERIPHERAL T CELL LYMPHOMA

EHA Library, Steven Horwitz, 214746

THE COMBINATION OF IBRUTINIB, LENALIDOMIDE, AND RITUXIMAB (IR2) IS ACTIVE IN RELAPSED/REFRACTORY (R/R) NON−GERMINAL CENTER-LIKE (NON-GCB) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): INTERIM ANALYSIS

EHA Library, Radhakrishnan Ramchandren, 214747

QUALITY OF LIFE IN CUTANEOUS T-CELL LYMPHOMA SUBJECTS TREATED WITH THE ANTI-CCR4 MONOCLONAL ANTIBODY MOGAMULIZUMAB VERSUS VORINOSTAT: RESULTS FROM THE PHASE 3 MAVORIC TRIAL

EHA Library, Pietro Quaglino, 214748

ANALYSIS OF CNS RELAPSES RISK FACTORS IN A POPULATION OF 1615 UPFRONT DLBCL PATIENTS TREATED IN LYSA PROTOCOLS LNH03 AND LNH07-3B

EHA Library, Sophie Bernard, 214749

SUBSTITUTION OF CISPLATIN FOR CARBOPLATIN OR OXALIPLATIN IN THE DHAP REGIMEN IS ASSOCIATED WITH IMPROVED SURVIVAL IN RELAPSED/REFRACTORY NON-HODGKIN’S LYMPHOMAS

EHA Library, Eloit Martin, 214750

VCAP-AMP-VECP VERSUS CHOP AS FIRST-LINE CHEMOTHERAPY FOR AGGRESSIVE ADULT T-CELL LEUKEMIA-LYMPHOMA: A PROPENSITY SCORE ANALYSIS

EHA Library, Shigeo Fuji, 214751

POSSIBLE FACTORS ON EFFICACY AND SAFETY OF CAR–T THERAPY IN RELAPSED OR REFRACTORY AGGRESSIVE B-CELL LYMPHOMA

EHA Library, Haiwen Huang, 214752

TITLE: LENALIDOMIDE PLUS R-CHOP THERAPY PROVIDES DURABLE LONG-TERM REMISSIONS IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): COMBINED ANALYSIS FROM TWO PHASE 2 TRIALS.

EHA Library, Annalisa Chiappella, 214753

FRONT-LINE TREATMENT OF DLBCL WITH 6 VERSUS 8 CYCLES OF R-CHOP IS NOT ASSOCIATED WITH INFERIOR SURVIVAL IN ELDERLY PATIENTS: RESULTS FROM A RETROSPECTIVE ANALYSIS OF THE SEER-MEDICARE DATABASE

EHA Library, Aijing Shang, 214754

MONITORING OF RHOA G17V MUTATION DURING THE COURSE OF THERAPY IN PATIENTS WITH ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA BY QUANTITATIVE ALLELE-SPECIFIC PCR WITH LNA-MODIFIED PRIMERS

EHA Library, Yulia Sidorova, 214755

CHARACTERISTICS, TREATMENT PATTERNS AND OUTCOME OF ELDERLY SYSTEMIC T/NK CELL LYMPHOMA IN A RESOURCE-LIMITED COUNTRY: THE RESULT OF THAILAND NATIONWIDE LYMPHOMA REGISTRY

EHA Library, Kitsada Wudhikarn, 214756

RETROSPECTIVE ANALYSIS OF PATIENTS WITH PRIMARY CENTRAL NERVOUS LYMPHOMAS TREATED WITH METHOTREXATE-BASED REGIMEN FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT AND TEMOZOLOMIDE MAINTENANCE

EHA Library, Maria Ljungqvist, 214757

RITUXIMAB, GEMCITABINE AND OXALIPLATIN (R-GEMOX) IN REFRACTORY/RELAPSED PATIENTS NOT CANDIDATES FOR HIGH-DOSE THERAPY WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL). A SINGLE CENTER STUDY OF 115 PATIENTS

EHA Library, Clarisse Cazelles, 214758

THE HIGH EXPRESSION OF CD38 IS ASSOCIATED WITH POOR PROGNOSIS IN DE NOVO DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Kaoru Sueoka, 214759

PROGNOSTIC FACTORS IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL) UNDER RITUXIMAB-CHOP (R-CHOP) CHEMOTHERAPY WITH OR WITHOUT RADIOTHERAPY (RT)

EHA Library, Theodoros Vassilakopoulos, 214761

SOLUBLE INTERLEUKIN-2 RECEPTOR AS A SURROGATE BIOMARKER OF METABOLIC TUMOR VOLUME MEASURED BY 18F-FDG PET/CT IN DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Hajime Senjo, 214762

TAK-659 PLUS BENDAMUSTINE (+/-RITUXIMAB), GEMCITABINE, LENALIDOMIDE, OR IBRUTINIB IN PATIENTS (PTS) WITH ADVANCED NON-HODGKIN LYMPHOMA (NHL)

EHA Library, Sarit Assouline, 214763

82RB PET FOR EARLY DETECTION OF DOXORUBICIN-INDUCED CARDIOTOXICITY

EHA Library, Adam Høgsbro Laursen, 214764

IMPACT OF OMISSION/REDUCTION OF VINCRISTINE FROM R-CHOP THERAPY IN TREATMENT OF GCB TYPE DLBCL

EHA Library, Shoko Marshall, 214765

EPIDEMIOLOGY AND TREATMENT PATTERNS IN LATIN AMERICAN PATIENTS WITH NON-HODGKIN’S LYMPHOMA: FINDINGS FROM THE HEMATO-ONCOLOGY IN LATIN AMERICA (HOLA) OBSERVATIONAL REGISTRY STUDY

EHA Library, Miguel Pavlovsky, 214766

CLINICAL RESPONSE AND PHARMACOKINETICS OF BENDAMUSTINE AS A COMPONENT OF SALVAGE R-B(O)AD THERAPY FOR THE TREATMENT OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)

EHA Library, Deok-Hwan Yang, 214767

OUTPATIENT SYSTEMIC HIGH-DOSE METHOTREXATE AS CNS PROPHYLAXIS IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Ruben Fernandez, 214768

OUTCOME OF A 10-YEAR POPULATION-BASED COHORT OF DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS IN THE FIRST-LINE, REFRACTORY AND RELAPSED SETTING: ‘REAL-WORLD’ DATA IDENTIFY SUBGROUPS IN NEED OF NEW THERAPIES

EHA Library, Hilde van der Galien, 214769

LOW SUNLIGHT EXPOSURE AT TIME OF DLBCL DIAGNOSIS MAY BE ASSOCIATED WITH INFERIOR SURVIVAL IN ELDERLY WOMEN

EHA Library, Anna Elinder Camburn, 214770

THE PROGNOSTIC ROLE OF 18FDG-PET/TAC AT THE END OF FIRST LINE CHEMO-IMMUNOTHERAPY IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA: A MONOCENTRIC STUDY ON 308 PATIENTS.

EHA Library, Elena Maiolo, 214771

CLINICAL CHARACTERISTICS AND OUTCOMES OF BURKITT LYMPHOMA IN A DEVELOPING COUNTRY

EHA Library, Vanderson Rocha, 214772

AN INCREASED RISK OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER IN CHILDREN AFTER CARDIAC TRANSPLANTATION FOR CONGENITAL HEART DISEASE

EHA Library, Ugonna Offor, 214773

ASSESSMENT OF IMMUNE FUNCTION BEFORE AND AFTER TREATMENT WITH RECOMBINANT FACTOR VIII FUSED WITH FC FRAGMENTS

EHA Library, Stephanie P'ng, 214774

FACTOR VIII RECOVERY TEST IN PERIOPERATIVE MANAGEMENT OF ORTHOPEDIC SURGERY IN ADULT PATIENTS WITH SEVERE HEMOPHILIA A

EHA Library, Jae Joon Han, 214775

PREDICTION OF INHIBITORS IN HAEMOPHILIA PATIENTS BY SCORE IN ONE CENTER

EHA Library, Oleksandra Stasyshyn, 214776

REAL WORLD SWITCHING FROM CONVENTIONAL FVIII PRODUCTS TO RFVIIIFC IN FRANCE, GERMANY, ITALY AND THE UK

EHA Library, Persefoni Kritikou, 214777